Gerald W. Crabtree - Aug 10, 2021 Form 3 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Role: Chief Science Officer, Director
Signature: /s/ Gerald W. Crabtree
Stock symbol: PMCB
Transactions as of: Aug 10, 2021
Transactions value $: $0
Form type: 3
Date filed: 8/31/2021, 06:23 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	PMCB	Common Stock						11.2K	Aug 10, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	PMCB	Stock Option (right to buy)							Aug 10, 2021	Common Stock	1K	$156.00	Direct	F1, F2
holding	PMCB	Stock Option (right to buy)							Aug 10, 2021	Common Stock	1K	$83.70	Direct	F1, F2
holding	PMCB	Stock Option (right to buy)							Aug 10, 2021	Common Stock	1K	$74.25	Direct	F1, F2
holding	PMCB	Stock Option (right to buy)							Aug 10, 2021	Common Stock	1K	$61.20	Direct	F1, F2
holding	PMCB	Stock Option (right to buy)							Aug 10, 2021	Common Stock	1K	$10.05	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").
F2	The exercise price has been adjusted to reflect the Reverse Split.
F3	The option vested in twelve equal monthly installments beginning on January 1, 2021.